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BACKGROUND: The use of chemotherapy in advanced metastatic breast cancer remains a subject of 
controversy. The thought of MicKinnon et al (early 1950s)  that the course of breast cancer was 
unaffected by chemotherapy has been refuted by results of treatment in the developed countries. The 
poor result of treatment in developing centres still compares with prechemotherapy era.  Consequently, 
The McKinnon’s thought may still lurk. We compared the survival of chemotherapy treated with 
chemotherapy untreated cancer of breast patients. 
METHOD: Records of breast cancer patients  who presented and died between January 2010 and May 
2014 were reviewed. The primary outcome was overall survival. Records of patients that received 
chemotherapy with or without other tumor directed specific therapy were compared with records of 
patients who did not receive any tumor directed therapy.   
RESULT: Thirty-one patients received chemotherapy while 25 patients did not. All were females, more 
than 90% were of the patients had advanced or metastatic disease. Treatments were not biologically 
directed and treatment plans were largely compromised and suboptimal. The overall mean survival was 
19.2 ±9.2 months, and the median duration was 17.5 months(range  6-44months). The overall survival 
was not statistically different between the two groups (p= 0.230, unequal variance assumed).  The 
objective of using neoadjuvant chemotherapy for fungating lesions was not achieved. 
CONCLUSION: In advanced and metastatic breast cancer, outcomes of patients who receive suboptimal 
regimen of cytotoxic chemotherapy do not differ from chemotherapy untreated patients. 





Controversies trail the use of chemotherapy for 
advanced and metastatic breast (1-3). In the early 
1950s, McKinnon (4) and other spractioners 
thought that the survival of breast cancer was 
predetermined (4). Today, in the developed 
countries where 80% of breast cancer patients 
present early; there is evidence that optimal 
chemotherapy prolongs survival in early, 
advanced and probably metastatic disease (2, 5). 
Therefore, the thoughts held by the proponentsof 
McKinnon have abated. In developing countries, 
8o% of breast cancer patients present  late, and the 
outcome of management can begenerally 
described as gloom (6-11). Consequently, it is 
natural for some clinitians to be worried by the 
thoughts held by the advocatesof McKinnon more 
than half a century ago. Reports of cancer survival 
studies are scanty from developing countries. 
1
Department of Surgery, University of Ilorin and  University of Ilorin Teaching Hospital, Kwara State, Nigeria  
2
Department of Surgery, Ladoke Akintola University of Technology and Ladoke Akintola Univeristy of Technology 
Teaching Hospital Ogbomoso, Oyo State, Nigeria
  
3





Pain and Palliative Unit. University of Ilorin Teaching Hospital, Ilorin, Kwara , Nigeria 
5
Ekiti State University, Ekiti State, Nigeria 
Corresponding Author: Agodirin Olayide, Email: cancer1992@yahoo.com 





Twenty years ago, Chiedozi (8) in Nigeria noted 
that the survival of advanced breast cancer was 
abysmally low. He compared the figures with 
those obtained in the developed countries about 
half a century earlier (in the 1940s). Today, 
figures quoted in Nigeria and some other 
developing countries are not distinctly different 
from chiedozi’s (5,7,8,11, 12) . Does this mean 
that despite worldwide improvements in cancer 
care, our results still remain at par with the results 
obtained in the developed countries in the late 
1940s?  
The biology of breast cancer differs between 
Caucasians and Africans; the pattern of 
presentation, facilities for diagnosis, treatment and 
the response to treatment also differ (8,11,12). 
Despite these facts, many literatures from 
developing countries commonly appraise the 
outcomes of their patient management   in the 
light of the results obtained in developed 
countries. It is rare to find direct comparison with 
untreated cases because the untreated patients 
commonly abscond. It is also rare to find 
comparison of current outcomes with outcomes 
obtained before the advent of better clinic-
pathologic understanding and more effective 
chemotherapy because of poor records. The 
implication of always comparing results from 
developing centres with those from developed 
countries is that we may be comparing diseases 
that bear different biology and have received 
different treatments. This will obscures the true 
values of our  results. For this reasons and for the 
first time in our centre, we compared the outcome 
of patients diagnosed of breast carcinoma who did 
not receive any tumor directed specific treatment 
with the outcome of those that received 
chemotherapy with or without other tumor 
directed specific treatment. This study aimed to 
obtain information about the effectiveness of 
chemotherapy treatment of advanced and 
metastatic breast cancer, directly compared to the 
“untreated” cases, in a resource poor setting. We 
also aimed to generate data for subsequent 
appraisal of outcome of management of this 
cohort of patients in resource poor centers without 
recourse to data from developed centers where 




PATIENTS AND METHOD 
 
This is a retrospective  study conducted at the 
University of Ilorin Heaching Hospital in Kwara 
State, Northcentral Nigeria. The hospital receives 
breast cancer patients and referrals from the state 
in which it is located and from neighboring states 
in Northcentral and Southwestern Nigeria.  
We reviewed case notes and pain and 
palliative unit records of patients diagnosed of 
cancer of the breast between January 2010 and 
May 2014. We included all available records of 
patients who presented and died within the study 
period because we sought uncensored duration of 
survival. Information extracted were the 
demographic characteristic, duration of illness 
before presentation, duration of illness from time 
of presentation until demise (i.e. hospital survival) 
and the stage at presentation. The overall survival 
was derived as a sum of the duration of illness 
before presentation and the hospital survival. The 
responses to treatments were also noted. 
The administration of chemotherapy or 
otherwise was the basis for grouping. We 
separated  the records into  those that received  
tumor directed cytotoxic chemotherapy with or 
without other specific therapies as group1 and 
those that did not receive any tumor directed 
specific therapy as group 2.  
The demographic characteristics were 
presented in descriptive statistics. Time to event 
(duration of survival) was presented with survival 
curve. Distribution of the data was checked with 
Shapiro-Wilk test and visual observation of the Q-
Q plot before selection of appropriate inferential 
statistical method. P-value < 0.05 was considered 
significant.  
Because we included all available complete 
records, the minimum sample sizes that would 
generate the. calculatedp-values were determined 
post hoc by using the R-statistical software.  In an 
attempt to control  for the effect of the stage of 
presentation on the survival, we conducted an 
exploratory subgroup analysis of stage III and IV 
disease. The theoretically underpowered subgroup 
analysis was  further explored by conducting 
simulation resampling generation and comparison 
of confidence interval of a hundred means using 
R-statistical software. There was no attempt to 
control for the performance status, the type/brand 
of chemotherapy and the complications recorded. 
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We excluded patients whose diagnoses were not 
carcinoma, those with recurrent disease and those 
who died of other causes. Records from which the 
overall survival could not be calculated were also 
excluded 
.   
RESULT 
 
Seventy one records were available, but only 56 fit 
the inclusion criteria. Six case notes could not be 
traced. Four records were excluded because they 
were recurrent diseases; 2 were excluded because 
the final diagnosis was phylloides and stroma 
tumor; 2 were excluded because the overall 
survival could not be calculated, and 1 was 
excluded because the patient died of cardiac 
failure. All were females. Stages recorded at 
presentation were II(2,3.6%), III(24,42.9%) and 
IV(30,53.6%).The overall mean age at 
presentation was 47.7±11.7 (range 31-80 years). 
The distribution of the stages and complications 
clinically recognized in the course of manegement 
are shown in Table 1. 
At the time of this report, in our center, 
biological profiling was not regular, and staging 
investigation was not exhaustive. The treatment of 
diagnosed patients was pre-planned (not 
biologically directed). The preferred treatment for 
early breast cancer was modified radical 
mastectomy followed by adjuvant 
polychemotherapy. Operable and resectable 
advanced and metastatic disease were offered 
simple mastectomy, axillary dissection and 
postoperative of adjuvant polychemotherapy. 
Hormonal therapy was prescribed for all patients 
concurrently with the polychemotherapy. 
Neoadjuvant chemotherapy was prescribed where 
necessary. Anthracycline (epirubicin) based 
polychemotherapy was the first line. Patients who 
could not afford the appropriate therapy were 
given cheaper and less effective agents. Patients 
who could not afford the drugs on schedule were 
treated as they procured their drugs and those who 
could not afford the full dose were given 
suboptimal dose. Brand of drugs and outlet of 
purchase were uncontrolled. 
Patients who refused specific tumor directed 
therapy or who could not have specific tumor 
directed therapy were managed symptomatically 
and followed up by the respective units and pain 
and palliative unit. Those who discharged against 
medical advice or absconded from the hospital 
were traced by the pain and palliative unit. 
 
Table1: Distribution of clinical stage at 
presentation and recorded complications  
 
Variable Group 1          Group2 
           Clinical 
Stage 
  
I 0 0 
II 2 0 
III 16 5 
IV 13 20 
Local 
complication   
Ulcerated 3 6 
fungated 12 6 
   
Solitary 
metastasis   
Lung 4 2 
Liver 0 3 
Long bone 2 0 
Brain 1 1 
Vertebra 1 1 
Multiple 
metastasis   
Lung and Liver 4 4 
Lung and Long 
bone 1 0 
Liver and Brain 1 0 
 
The overall mean survival from time of noticing 
the first symptom(s) was 19.2 ±9.2 months and the 
median duration was 17.5 months (range  6-
44months). Thirty-one patients had tumor directed 
specific treatment (group1), while 25 patients had 
no tumor directed specific treatment (group 2). 
Shapiro-Wilk normality test for overall survival 
yielded a p-value of 0.02 (Gaussian distribution) 
and 0.289 (not Gaussian distribution) for groups 1 
and 2 respectively. The visual observation of the 
Q-Q plot also suggested that group 2 data was not 
Gaussian distribution (Figures 1).  






           Figure1: Q-Q Plot for both groups- Group1 shows 
gaussian distribution; group 2 shows non-gaussian 
distribution 
 
In the unsegregated analysis, the overall survival 
was not statistically different between the two 
groups (Table 2 and Figure2, p= 0.230, unequal 
variance assumed). The underpowered stage 3 
subgroup exploratory analysis suggested longer 
survival in the chemotherapy group (Table 2). 
Further exploratory analysis by simulation 
resampling method yielded a p value of <0.001 
also in favor of better survival in the 
chemotherapy group. A boxplot and the 95% 
confidence limit by percentile and the standard 
error methods were in agreement (Figure 3 and 4) 
suggesting that there are possibly two separate 
survival groups. The confidence limits by the 
standard error method were 10.1, 12.8 and 4.4, 6.6 
for groups 1 and 2 respectively (Figure 4). 
 
           Table2: Comparison of the demographic characteristics and the unsegregated overall and segregated   






p-value(t ) Minimum sample size 
on each side required to 
obtain the p-value 
Age at presentation 45.6±10.7(n=28) 49.314. 
±1(n=16) 
0.366 (t=0.920) 13 
Duration of symptom 
before presentation  
9.57. ±1(n=31) 12.4±9.2 (n=25) 0.200 (t=1.289) 14 
Hospital survival 11.6±7.1 (n=31) 5.1±5.2(n=25) <0.001 
(t=3.880) 
13 
Overall survival (stage 
unsegregated) 
20.9±8.4 (31)n= 17.5±9.3 (n=25) 0.166 (t=1.443) 13 
Stage III 21± 9.9(n=16) 15 ± 1.6(n=5) 0.047 (t=2.126) 9 





          Figure2: Survival curve comparing the duration of survival of the two groups (stage unsegregated)  
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Figure 3: Boxplot of 100 bootstrap means of 




Figure 4: Confidence limit (percentile method) of 
100 bootstrap means of stage 3 survival for 
groups 1(Grp1)  and 2(Grp2)  
 
The estimated numerical widest diameter of the 
breast mass(es) at presentation was documented 
for 30% of the patients (median 6cm, range 1-
20cm). The others were described as a fraction of 
the size of the breast, as huge, fungation or not at 
all.   
All patients had psychosocial support, 
analgesics, antibiotic, wound management and 
blood transfusion as appropriate for their 
presentation. All patients in group1 had 
chemotherapy, 8 had mastectomy and axillary 
dissection. The intention of chemotherapy was 
neoadjuvant in 16 patients, neoadjuvant and 
adjuvant in 9 patients and adjuvant in 6 patients. 
The number of group1 patients that were regular 
on hormone therapy could not be ascertained from 
the records. None of the group 2 patients had 
chemotherapy, hormonal therapy or mastectomy. 
Among group 2 patients, the reason for not 
receiving treatment was explicitly documented in 
12 of the 25 the patients. The reasons were cost, 
poor performance status, absconding, defaulting of 
clinic visits and refusal to treatment. Of the 
group1 patients, 18 had anthracycline based 
treatment, 5 had taxane based treatment, while 2 
had taxane and anthracycline at one time or the 
other. The exact combination of chemotherapy 
could not be determined from the records in 6 
patients. The number of chemotherapy doses 
received by group1 patient ranged from 1 to 12. 
The median number of doses was 4. Thirty percent 
received less than 3 doses because of reasons 
similar to those who did not receive chemotherapy 
at all.  
The progression of the disease was not 
explicitly documented for many patients; however, 
from scrutiny of the records, we found that in 
group 2, two patients presented with ulceration, 
while 4 progressed to ulceration. Five presented 
with fungation, while 1 progressed to fungation. In 
group1, 12 presented with already fungating 
lesion, 1 presented with ulcerated lesion and 2 
progressed to ulceration while on 
polychemotherapy. Healing of ulceration was 
documented for 1 patient and reduction in size of 
the lesion was also documented for 1 lesion. None 
of the fungating lesions healed or improved 
enough to be offered toilet mastectomy before 




Even though we know that suboptimal therapies 
are practised in the chemotherapy treatment of 
breast cancer (5, 7,10,13,14, 15), the aim of this 
study was not to determine this. Rather, it was 
aimed to determine the effectiveness of 
chemotherapy in a poor resource setting compared 
to untreated patients. The adduced reasons for 
continuing use of suboptimal therapy are: firstly, it 
is considered unethical not to offer treatment, 
secondly the hope that half treatment may be 
better than no treatment and lastly because of the 
fear that no tumor directed treatment may be an 
admittance of defeat (16).  
In this article, overall survival was the 
primary measure of outcome because it is difficult 
to obtain other measures of outcome in a 





retrospective review due to poor records. The 
mean duration of survival of untreated group 2 
patients was about 17months.   The  unsegregated 
analysis showed no significant difference in 
overall survival between the two groups (Table2). 
This finding is not surprising because more than 
90% of the patients in this study were advanced 
and metastatic. When we   compared stages III and 
IV between the two groups, the stage III who 
received chemotherapy seemed to show a better 
survival (see Table 2). Further exploratory 
analysis by simulation of 100 resampling means 
also supports this (Figures 3 and 4). Perhaps, this 
suggests that even with the current suboptimal 
treatment modalities, the stage III patientsare 
benefiting from effect of chemotherapy. However, 
this was just an exploratory result obtained after 
an underpowered subgroup theoretical analysis  
supported by a simulation resampling method. 
Therefore, firm pronouncement cannot be made. 
There was also a significant difference in the 
hospital survival which we consider a lead time 
bias (Table 2). 
Considering the objective response rate in 
fungation and ulceration, we do not think that the 
patient who had chemotherapy had a better 
response. This conforms with findings 
documented elsewhere in Nigeria where tumors 
are large (10, 17), but contrary to chiedozi’s 
findings where the chemotherapeutic dosing and 
scheduling were optimal (8,17).  
The trio of gloomy outcome, prohibitive cost 
of therapy and discouraging side effects of the 
drugs (7) constitute “a lose-lose and lose 
situation” that may serve as deterrent to orthodox 
care as reported earlier (7). If the suboptimal 
treatment is inferior to the standard treatment as 
previously noted(13, 14)  and is not different from 
results in “untreated” cases as suggested by this 
study, then we wonder whether it is ethical to 
recommend an all –or –none treatment protocol 
where specific tumor directed chemotherapy is 
reserved  for those who will receive the optimal 
therapy. This triggers   a controversial hypothesis 
stating that “in advanced and metastatic breast 
cancer, the overall survival of patient who receive 
suboptimal cytotoxic chemotherapy do not differ 
from “untreated” patients”. Alternatively, we 
should determine the limits below which the 
compromised/suboptimal treatment ceases to be 
better than no tumor directed treatment.  
Loibl etal (15) stated that it is not known 
whether sub-optimal chemotherapy is detrimental 
to the course of breast cancer, while Hershman 
etal (13) stated that suboptimal chemotherapy is a 
predictor of poor survival. The primary results in 
this study support the later statement thus again 
question the unreserved deployment of suboptimal 
chemotherapy treatment. However, the 
exploratory subgroup analysis indicates that  in 
certain circumstances suboptimal therapy may not 
be totally futile. 
There were several limitations in this study. 
This is because by necessity studying untreated 
cancer of the breast patients is typically a 
retrospective study and retrospective studies have 
the limitation of missing records. We were able to 
collect this volume of untreated records because of 
the home visitations and tracing efforts of the pain 
and palliative team. Firstly, the overall survival 
was the only complete measure outcome. The 
treatment group was heterogeneous. Some of the 
patients in group1 received other tumor directed 
specific therapies in addition to chemotherapy. 
However, the primary focus of this article is on the 
effect of chemotherapy because it is the advent of 
chemotherapy in the neoadjuvant or adjuvant 
context that has revolutionized the treatment of 
advanced breast cancer (2, 18). Secondly, the 
overall duration of survival was dependent on the 
patients’ memory. Therefore, there is risk of recall 
bias. The staging method was not exhaustive; 
hence; it is possible that most of the patients had 
metastatic disease ab-initio. Thirdly, we reviewed 
only records of patients who died of the disease. 
Thus, it could be argued that we selected patients 
who had aggressive disease, but we must add that 
just as there were patients who received 
chemotherapy that have survived longer than the 
duration of this study, there were also those that 
did not receive chemotherapy that were still alive 
beyond the duration of this study.  
And lastly, about 33% of the patients who 
received chemotherapy received just 1 or 2 cycles; 
hence; this may be consideredas no chemotherapy. 
However, because we expect that each dose of 
chemotherapy should have effects on the 
symptoms of the disease and should be 
independent of the effect of subsequent or 
previous doses, we had to consider any number of 
dose(s) as received treatment and the analysis had 
to be based on intention to treat. 
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Many of the limitations of breast cancer care 
reported in this study have been previously 
recognized, but they linger todate. Adisa et al (5) 
in Southwestern Nigeria noted non-adherence to 
schedule and the use of less optimal choice of 
chemotherapy. As mundane as the limitations of 
breast cancer care in resource poor centres may 
sound, now we recognize how seriously they may 
be impacting our care, and this corroborates the 
statement credited to Loibl (15) et al that the 
consequences of dose reduction and delays are 
significant.   
In conclusion, this study questions the 
unreserved suboptimal use of chemotherapy as is 
currently practised. It suggests that our results are 
not only inferior to developed centres, they may 
also in fact just be comparable to the “untreated” 
probably due to the sub-optimal therapies. 
Therefore, we suggest the systematic assessment 
and re-direction of our treatment strategies. We 
also state that there is the need for insurance 
schemes to support diagnostic process  to fund 
treatment of breast cancer in developing centers so 
that we can begin to administer appropriate 
treatment to the appropriate disease if we want to 
move forward on a problem recognized more than 
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